Press Releases
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line (1L) treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA), have been presented as a poster presentation at the 2026 ASCO Annual Meeting on May 30, 2026, 13:30 – 16:30, CDT. The poster was titled "Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer – a subgroup analysis" [1]...
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients in this cohort...
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression . The 3→ 1.5 mg/kg dose group (n=22) showed ORR of 86.4% , confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR of 100% The second stage of the PoC study is ongoing in head-to-head comparison vs...
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communications, initiation of a global Phase 3 clinical study of IBI363 for IO-resistant non-squamous NSCLC is also planned. Innovent and Takeda are co-developing IBI363 (Takeda R&D code: TAK-928) globally...
BriaCell Therapeutics Announces Pricing of Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts offering of 1,449,300 common shares. Each common share is being sold at an offering price of $3.25 per share. All of the common shares in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting placement agent's fees and other offering expenses, are expected to be approximately $4.7 million. The offering is expected to close on June 2, 2026, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq...
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company's apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting...
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced updated efficacy and safety data from a clinical study of its first approved product, olverembatinib (HQP1351), as a second-line therapy in patients with chronic-phase chronic myeloid leukemia (CML-CP) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting...
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced results from a Phase Ib study evaluating olverembatinib (HQP1351), the company's core product, in combination with bispecific T-cell engager antibody (immunotherapy) blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (Ph+ BCP-ALL) were presented in a rapid oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting...
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Total Sales and Shipments of EAI Robots Reached 69 Units in May, a New Record, Exceeding the Combined Total for the Months of March and April
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to Issue 57 of our weekly report. In the final week of May, we would like to highlight two pieces of good news: first, total sales and shipments of EAI robots reached 69 units in May, exceeding the combined total for...
Atlas Salt Announces $10 Million Bought Deal LIFE Financing
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Cango Inc. Reports First Quarter 2026 Unaudited Financial Results
DALLAS, May 31, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG) ("Cango" or the "Company"), a leading Bitcoin miner leveraging its global operations to develop an integrated energy and AI compute platform, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter of 2026 Financial and Operational Highlights Financial Performance: In the first quarter of 2026, the Company generated total revenue of US$102.0 million, primarily driven by US$98.4 million from its Bitcoin mining business...
As Global Markets Reach New Highs, Growing Numbers of Microcap and Penny Stock Investors Worldwide Are Discovering ELEKTROS Inc.-A Unique Opportunity at an Early-Stage Valuation as Momentum Continues Building Across the Investment Community
ELEKTROS Inc. - Publicly Traded (Ticker Symbol:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / May 31, 2026 / As U.S. financial markets continue rallying and investor optimism expands throughout the global investment landscape, management believes renewed enthusiasm surrounding emerging growth companies and microcap opportunities continues accelerating across worldwide markets. Management further stated that increasing investor attention toward lithium supply chains, EV infrastructure, and next-generation charging technologies continues strengthening as more investors globally continue discovering the long-term vision and growth potential of ELEKTROS Inc. Reuters recently reported that expanding high-speed charging infrastructure remains one of the most important components necessary for accelerating electric vehicle adoption worldwide, as governments and major corporations continue investing billions into EV charging expansion initiatives...
Berkshire Hathaway to Acquire Taylor Morrison Home Corporation for $8.5 Billion
All-cash transaction delivers significant and certain value for Taylor Morrison shareholders; purchase price represents approximately 24% premium to latest closing stock price Transaction provides attractive opportunity for Taylor Morrison team members and partners to execute continued growth trajectory with the strength of Berkshire Hathaway SCOTTSDALE, Ariz. and OMAHA, Neb...
As Global Markets Surge to New Highs, Investors Worldwide Are Discovering ELEKTROS Inc. - A Rare Opportunity in Lithium Mining, Rare Earth Minerals and Advanced EV Patent Technology as Growing Momentum Continues Capturing the Attention of Microcap and Penny Stock Investors Across the Globe
ELEKTROS Inc. - Publicly Traded (Ticker Symbol:ELEK) WEST PALM BEACH, FL / ACCESS Newswire / May 31, 2026 / As U.S. financial markets continue rallying and investor optimism expands throughout the global investment landscape, management believes renewed enthusiasm surrounding emerging growth companies and microcap opportunities continues accelerating across worldwide markets. Management further stated that increasing investor attention toward lithium supply chains, EV infrastructure, and next-generation charging technologies continues strengthening as more investors globally continue discovering the long-term vision and growth potential of ELEKTROS Inc. Reuters recently reported that expanding high-speed charging infrastructure remains one of the most important components necessary for accelerating electric vehicle adoption worldwide, as governments and major corporations continue investing billions into EV charging expansion initiatives...
Diana Shipping Inc. Sends Letter to Genco Shipping & Trading Shareholders Making the Case for Electing Six Independent Nominees With Proven Track Records of Creating Shareholder Value
Details Why the Entrenched Genco Board Should Not Be Trusted to Act in Shareholders' Best Interests Contrasts Diana's Six Accomplished, Independent Nominees Against a Board That Has Spent Six Months and Over $13 Million Protecting Itself and Management Releases Video Message to Genco Shareholders from CEO Semiramis Paliou Outlining the Compelling Value of Diana's Offer and the Urgent Need for Board Change Calls on Genco Shareholders to Elect a Board That Will Finally Put Shareholders First by Voting the GOLD Universal Proxy Card "FOR" Diana's Six Independent Director Nominees ATHENS, Greece, May 31, 2026 (GLOBE NEWSWIRE) -- Diana Shipping Inc. (NYSE: DSX) (“Diana” or “the Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels that is the largest shareholder of Genco Shipping & Trading Limited (NYSE: GNK) (“Genco”), today sent an open letter to Genco shareholders making the definitive case for electing Diana's six independent director nominees to the Genco Board of Directors (the “Genco Board”) — Gustave Brun-Lie, Paul Cornell, Chao Sih Hing Francois, Jens Ismar, Viktoria Poziopoulou and Quentin Soanes — at Genco's 2026 Annual Meeting of Shareholders to be held on June 18, 2026. In today's letter, Diana draws a sharp contrast between its six independent nominees — accomplished shipping, finance, M&A and legal executives with proven track records of creating and maximizing shareholder value — and the entrenched Genco Board, which has consistently prioritized management's compensation and control over the interests of the shareholders it is supposed to represent...
UGRO: urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 Player Auction Set for June 1, 2026 @ 5:00 AM EDT (2:30 PM Colombo Time)
Worldwide Fans Invited to Follow Live at https://lpl.flashsportsandmedia.com
iHuman Inc. Announces Acquisition of Businesses and Assets Related to All Knowledge and Perfect Lingo
BEIJING, May 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE: IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced that it has entered into certain asset transfer agreements to acquire the businesses and assets related to two products, All Knowledge (全知识) and Perfect Lingo (万词王) (the "Acquisitions"), for an aggregate consideration of RMB94.0 million, subject to potential two-way price adjustments and contingent earn-out payments. All Knowledge is an app that focuses on humanities and AI literacy, providing users with AI-powered interactive access to knowledge across history, culture, literature, philosophy, art, and other humanities fields...
GRABAR LAW OFFICE INVESTIGATES CLAIMS ON BEHALF OF SHAREHOLDERS OF ZOETIS, INC. (ZTS)
Philadelphia, Pennsylvania--(Newsfile Corp. - May 31, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Zoetis, Inc. (NYSE: ZTS).
CPKC to maintain rail operations across Canada during IBEW strike
CALGARY, AB, May 31, 2026 /PRNewswire/ - Canadian Pacific Kansas City (TSX: CP) (NYSE: CP) (CPKC) today said it has implemented contingency plans to maintain railway operations across Canada following the International Brotherhood of Electrical Worker (IBEW) Canadian Signals and Communications System Council No. 11's rejection of CPKC's latest contract offers...
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and sponsored by Summit's partner Akeso, Inc. (HKEX Code: 9926.HK), will be presented today as part of the Plenary Session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation is entitled “Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untrea...
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Houston, Texas and Tuebingen , Germany, May 31, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific (TCER) candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA. The data show a consistent and favorable tolerability profile across multiple tumor types and encouraging anti-tumor activity at the recommended Phase 2 dose (RP2D) with or without the immune checkpoint inhibitor (ICI) pembrolizumab. Results from the Phase 1 study are being published simultaneously in Nature Medicine ...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death 1
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform designed to accelerate drug development and research. This evolution seamlessly connects Tempus' multimodal data, AI tooling and computational infrastructure to deliver actionable insights at the pace required for drug development. The next-generation of the Lens platf...
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
More than one-third of responders with previously treated disease achieved complete responses, with median duration of response not yet reached, as reported in new Journal of Clinical Oncology publication RYBREVANT FASPRO™, an EGFR- and MET-targeting dual inhibitor, is the first and only subcutaneous therapy being evaluated in this setting Johnson & Johnson submitted a supplemental Biologics License Application to U.S. FDA seeking approval for this indication CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses...
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine CHICAGO, May 31, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease. The trial met both primary endpoints...
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Results simultaneously published in The New England Journal of Medicine Results simultaneously published in The New England Journal of Medicine
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer
Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the importance of comprehensive biomarker testing across all stages of disease These data will be published in the New England Journal of Medicine and simultaneously presented during the Plenary Session at the 2026 ASCO Annual Meeting INDIANAPOLIS, May 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC). The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) with selpercatinib reducing the risk of disease recurrence or death by 83% versus placebo in the primary analysis population...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma Data support selection of 160 mcg dose for the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced melanoma Clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance Brenetafusp was generally well tolerated as monotherapy and in combination with pembrolizumab (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md...
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented final first-in-human data for RP2 alone and in combination with nivolumab in patients with advanced solid tumors during an oral session at the 2026 American Society of Clinical Oncology annual meeting...
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) versus FOLFIRI with or without bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. These results will be...
GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer 71% of the New Cancers Detected by the Galleri Test Were in Stages I-III MENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1]...
SMX and the Age of Parity: Certified Recycling Becomes the New Economics of Plastic
NEW YORK CITY, NY / ACCESS Newswire / May 31, 2026 / Plastic has always been treated as one of the world's most dependable materials: inexpensive, scalable, lightweight, and available in enormous volumes. It protects food, moves medicine, reduces shipping weight, supports health care, enables packaging, and keeps everyday products affordable...
Nokia Corporation - Managers' transactions (Hanrahan)
Nokia CorporationManagers' transactions31 May 2026 at 13:00 EEST Nokia Corporation - Managers' transactions (Hanrahan) Transaction notification under Article 19 of EU Market Abuse Regulation.____________________________________________Person subject to the notification requirementName: Hanrahan, VictoriaPosition: Other senior manager Issuer: Nokia CorporationLEI: 549300A0JPRWG1KI7U06Notification type: INITIAL NOTIFICATIONReference number: 158758/5/6____________________________________________Transaction date: 2026-05-26Venue: XNYSInstrument type: SHAREISIN: US6549022043Nature of the transaction: ACQUISITION Transaction details(1): Volume: 22713 Unit price: 16.0179 USD Aggregated transactions(1): Volume: 22713 Volume weighted average price: 16.0179 USD____________________________________________Transaction date: 2026-05-28Venue: XNYSInstrument type: SHAREISIN: US6549022043Nature of the transaction: ACQUISITION Transaction details(1): Volume: 21969 Unit price: 15.5984 USD Aggregated transactions(1): Volume: 21969 Volume weighted average price: 15.5984 USD____________________________________________ Total aggregated transactions Volume: 44682 Volume weighted average price: 15.8117 USD About Nokia Nokia is a global leader in connectivity for the AI era. With expertise across fixed, mobile, and transport networks, we're advancing connectivity to secure a brighter world...
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) plus standard of care (SoC; androgen receptor pathway inhibitor [ARPI] + androgen deprivation therapy [ADT]) compared to SoC alone in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). These PSMAddition data were presented as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting...
As Global Markets Discover Elektros, Microcap and Penny Stock Investors Are Beginning To Take Notice of a Growing EV Patent Technology and Lithium Mining Company
WEST PALM BEACH, FL / ACCESS Newswire / May 30, 2026 / Elektros Inc. (OTC PINK:ELEK) is pleased to provide shareholders with an update regarding the Company's intellectual property initiatives surrounding U.S. Patent No. 12,522,100, entitled "Multi-Port Charging Assembly for Electric Vehicles.
SIX FLAGS FIESTA TEXAS UNLEASHES WEREWOLF GORGE, THE WORLD'S LONGEST FAMILY LAUNCH ROLLER COASTER
Record-breaking new coaster set for the park's 35th anniversary season features four launches, 32 airtime moments and unmatched family thrills Click for Werewolf Gorge Media Assets SAN ANTONIO, May 30, 2026 /PRNewswire/ -- Six Flags Fiesta Texas today announced Werewolf Gorge , a first-of-its-kind family launch roller coaster that delivers record-breaking thrills, immersive storytelling and a dynamic multi-generational experience unlike anything else in the world. Combining a unique mix of ride elements not found together on a single attraction — including four launches, a mid-course rollback and a 39-inch height requirement — Werewolf Gorge represents a true industry first and sets a new benchmark for family thrill attractions...
Global EV Charging Patent Update: Elektros Inc. Continues To Advance and Protect Its Intellectual Property as EV Infrastructure Opportunities Expand Worldwide
Elektros Inc. • Publicly Traded • Ticker Symbol:ELEK WEST PALM BEACH, FL / ACCESS Newswire / May 30, 2026 / Elektros Inc. (OTC PINK:ELEK) is pleased to provide shareholders with an update regarding the Company's intellectual property initiatives surrounding U.S. Patent No. 12,522,100, entitled "Multi-Port Charging Assembly for Electric Vehicles...
Global Microcap Investors Are Discovering a Rare Diamond in the Rough
WEST PALM BEACH, FL / ACCESS Newswire / May 30, 2026 / Elektros Inc. (OTC PINK:ELEK) is pleased to provide shareholders with an update regarding the Company's intellectual property initiatives surrounding U.S. Patent No. 12,522,100, entitled "Multi-Port Charging Assembly for Electric Vehicles.
Results of Annual General Meeting
Edmonton, Alberta--(Newsfile Corp. - May 30, 2026) - AuMEGA Metals Ltd (ASX: AAM) (TSXV: AUM) (OTCQB: AUMMF) ("AuMEGA" or "the Company") advise that at the Annual General Meeting of shareholders held today (28 May 2026 in Port Aux Basque, Newfoundland, Canada), all resolutions were passed on a poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, details of both the poll and valid proxy votes received, are shown on the following pages...
Pompa Program Surpasses 1,300 Trustpilot Ratings with 4.7/5 Star Average
More than 1,300 verified clients have rated the Pompa Program on Trustpilot, with an average of 4.7 out of 5 stars — a reflection of the real-world outcomes participants are experiencing. More than 1,300 verified clients have rated the Pompa Program on Trustpilot, with an average of 4.7 out of 5 stars — a reflection of the real-world outcomes participants are experiencing...
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
WHIPPANY, N.J.--(BUSINESS WIRE)--Primary results from the Phase II ARACOG (AFT-47) trial, a head-to-head randomized trial conducted by Alliance Foundation Trials LLC, showed that patients treated with NUBEQA (darolutamide; n=55) experienced significantly less decline in objective cognitive performance over 24 weeks compared with those treated with enzalutamide (n=56)...
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4 years Follow-up is ongoing; median duration of complete response has not yet been reached No new adverse safety events have been observed during long-term follow-up US FDA granted seven-year period of orphan drug market exclusivity to PAPZIMEOS GERMANTOWN, Md., May 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced updated long-term follow-up data from the pivotal study of PAPZIMEOS™ (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP)...
Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with an IND submission expected mid-2026 MORRISTOWN, N.J., May 30, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of a real world analysis supporting the therapeutic potential of targeting seizure related homolog protein 6 (SEZ6) with a next-generation ADC for the treatment of neuroendocrine tumors, including small cell lung cancer (SCLC)...
Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology
MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several of its lead programs at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including updated data for its EIK1001 trial in non-small cell lung cancer (NSCLC) and its highly selective PARP1 inhibitor EIK1003...
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%)...
BW LPG Enters Into Agreement for Eight 90'cbm Panamax Newbuildings with Hyundai Heavy Industries
SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”), the world's leading owner and operator of LPG vessels, announces that it has signed a contract for the construction of eight 90'cbm Panamax Very Large Gas Carriers (VLGCs), for a total consideration of about US$940 million, subject to the final technical specifications. The newbuildings are expected to be delivered sequentially from the start of 2029 until the second quarter of 2030. “This newbuil...
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026.
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease –
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held fr...
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the PRECISION Challenge, a national initiative engineered to accelerate the next generation of oncology breakthroughs leveraging its foundational model. The PRECISION Challenge aims to unlock breakthroughs in oncology at scale by providing access to data, funding, and expertise to multidisciplinary teams around the world who seek t...
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1 failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting...
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, CI: 0.39-0.65, p
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer with a 63% objective response rate (ORR), 50% confirmed ORR (cORR), including four complete responses, and longest ongoing response at 12 months Additional Phase 1 data for IMA203CD8 in heavily pretreated patients with synovial sarcoma showed deep and durable responses with a 67% ORR and 64% cORR, including one complete response, and ongoing responses up to ~3 years IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations Clinical anti-tumor activity observed across tumor types (ovarian carcinoma, uterine cancer, melanoma, synovial sarcoma) with distinct biology and differing levels of PRAME expression, including lower PRAME levels in ovarian carcinoma Clinical profile of IMA203CD8 supports continued development in gynecologic cancers and expansion into other PRAME-positive solid tumors Determination of recommended phase 2 dose (RP2D) remains expected in 2026 Houston, Texas and Tuebingen, Germany, May 30, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, USA...
GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting
No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round Annual Galleri Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively Galleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25% Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of Care GRAIL to Host Analyst Call From 2026 ASCO Annual Meeting MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced detailed clinical utility, performance and safety results from its landmark NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting1...
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold trial-in-progress poster presentations on the Phase 1/2a study of its lead targeted alpha radiotherapy candidate MP0712 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. ASCO takes place May 29-June 2 in Chicago, and SNMMI May 30-June 2 in Los Angeles...
Incyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients.
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed efficacy and safety results from RINGSIDE, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoid tumors. The data are being presented today in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual...
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) co-sponsored by Summit and Akeso, featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. The data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presentation, entitle...
Tempus Introduces ‘Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically significant insights that close the gap between the time of order and delivery of insights. Representing a significant paradigm shift in precision oncology workflows, Tempus Preview offers preliminary results in the critical window between when a diagnostic test is or...
SMX and the Age of Parity: Recycled Plastic Is No Longer a Sustainability Choice-It's an Economic Imperative
NEW YORK CITY, NY / ACCESS Newswire / May 30, 2026 / Recycled plastic is no longer just a sustainability gesture. For years, it was treated as a responsible choice, a brand signal, or a way for companies to show progress toward environmental goals.
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
STOCKHOLM, May 30, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 5,000 Class B shares during May for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 5,000 stock options of series 2019/2028...
Replenish Nutrients: Market Has Yet to Price in the H2 2026 Capacity and Licensing Inflection
MALMÖ, Sweden, May 30, 2026 /PRNewswire/ -- Company:Replenish NutrientsListings: CSE Canada , Frankfurt and US OTC Tickers: ERTH / VVIVF / WIMNMarket cap at time of publication: $28 MCADStock price at time of publication: $0.14 CADBusiness: Regenerative agricultureWebsite:https://replenishnutrients.com/ ESGFIRE Commentary Replenish Nutrients has delivered its Q1 2026 results, and while the quarter itself reflects a deliberate transition, the single data point that matters most is already on the tape: a 29% gross profit margin on granulated fertilizer at the Beiseker facility — squarely inside the Company's previously communicated 25–35% range. The unit economics are proven...
FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties (“FCPT” or the “Company”), is pleased to announce the signing of a definitive agreement to acquire up to 102 Mission Pet Health (“MPH”) veterinary properties for a purchase price of up to $268.0 million from Shore Capital Real Estate Partners Fund I. Mission Pet Health is one...
Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM
NEW ORLEANS, May 29, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC0, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences company and parent of the Vanta premium longevity brand, announces a proposed non-brokered private placement financing (the "Private Placement"), consisting of the issuance of an aggregate of up to 2,500,000 units of the Company (each, a "Unit"), at a price of $1.00 per Unit for aggregate gross proceeds of up to $2,500,000. Each Unit will consist of one common share in the capital of the Company (each, a "Share") and one transferable common share purchase warrant of the Company (each, a "Warrant"), with each Warrant entitling the holder to acquire one additional Share (each, a "Warrant Share") at a price of $1.25 per Warrant Share for a period of 24 months from the date of closing...
Fobi AI Provides Corporate Update Regarding FFCTO Revocation Process and Q3 Interim Filings
VANCOUVER, BC, May 29, 2026 (GLOBE NEWSWIRE) -- Fobi” or the “Company”), a leader in AI powered data intelligence and digital wallet solutions, today provided an update regarding the status of the Company's ongoing efforts in connection with the revocation of the existing failure to file cease trade order (“FFCTO”) and the resumption of trading of the Company's common shares on the TSX Venture Exchange (the “TSXV”)...
Global Compliance Completes Acquisition of Global People's Trust
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Global Compliance Applications Corp. (CSE: APP) (FSE: 2FA) (OTCQB: FUAPF) ("GCAC" or the "Company") is pleased to announce that, further to the Company's news release dated March 9, 2026, that the Company has acquired (the "Acquisition") a 100% interest in Global People's Trust LP and Global People's Trust (Management) Limited (together, the "Global People's Trust") pursuant to a Share Purchase Agreement (the "Definitive Agreement") with Darrence Hugh Christian (the "Seller"). In accordance with the Definitive Agreement and as consideration for a 100% interest in Global People's Trust, the Company has issued the Seller 38,000,000 common shares in the capital of the Company (the "Consideration Shares") at a deemed price of $0.015 per Consideration Share...
The FUTR Corporation Reports Financial Results for Q1 2026
Three-Month Period Ended March 31, 2026 Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) (FSE: QA20), creator of the FUTR Agent App which enables users to store, manage, access, and monetize their personal information and make intelligent payments (the "Company" or "FUTR"), today reported financial results for the three-month period ended March 31, 2026 (the "Quarter"). Period-over-period comparisons are made to the three-month period ended March 31, 2025...
Toogood Gold Signs Definitive Agreement for Option to Earn 100% Interest in the Table Mountain Project, Nevada
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Toogood Gold Corp. (TSXV: TGC) (OTCQB: TGGCF) (FSE: D3P) ("Toogood" or the "Company") today announced that it has entered into a definitive option agreement (the "Definitive Agreement") dated May 26, 2026 with Orogen Royalties Inc. and its subsidiary GenEx Exploration Inc. (collectively "Orogen"), and Altius Resources Inc. ("Altius"), and together with Orogen, the ("Vendors"), pursuant to which the Company has the exclusive right to earn a 100% interest in the Table Mountain Project (the "Project" or "Table Mountain"), located in Lincoln County, Nevada. Key Points Summary Definitive Agreement executed: Toogood has secured an exclusive option to earn a 100% interest in the Table Mountain Project in Nevada; Undrilled, district-scale low-sulphidation epithermal system: 4 x 2 km alteration footprint with multiple outcropping Au-Ag-bearing epithermal veins; Compelling first-pass geochemistry: Rock assays up to 2.6 g/t Au and >50 g/t Ag with strong Sb-As-Hg pathfinder anomalism, further supporting low-sulphidation epithermal affinity; No historical drilling: Large, well-preserved system remains effectively untested by modern exploration; Strategic location: 2-hour drive from Las Vegas and 10 km south of the Atlanta Gold Mine within the Indian Peak Caldera Complex; Aligned vendor structure: Equity-based earn-in with a 3.0% net smelter return ("NSR") royalty and staged buydown rights to 2.0%; Phase 1 exploration: Systematic property-wide campaign has commenced, including soil geochemistry (>6,150 samples), 1:5,000-scale structural and geological mapping, ground gravity, drone magnetics, prospecting, rock sampling and hand-held spectral analyses; Phase 2 exploration: Planned following Phase 1 and expected to include controlled-source audio-frequency magnetotellurics ("CSAMT") to map deeper resistive features, together with drill-target-focused mapping, prospecting and rock sampling; and Maiden drill program: Phase 1 exploration designed to deliver ranked drill targets and a permit-ready drill plan in Q3 2026...
CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements
HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating that the Company's closing bid price for its common shares fell below $1.00 per share for 30 consecutive trading days, which is not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. The Nasdaq notification does not affect CLPS's current listing or trading of the Company's securities on the Nasdaq Global Market...
Canadian Goldfields Appoints Harp Gosal as Director of Capital Markets and Communications
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Canadian Goldfields Discovery Corp. (TSXV: CGM) (OTCQB: CGMXF) ("Canadian Goldfields" or the "Company") is pleased to announce the appointment of Harp Gosal as Director of Capital Markets and Communications. The appointment reflects the Company's continued focus on strengthening its market engagement and communications platform as Canadian Goldfields advances its strategic objectives...
Core Critical Approved for Listing on OTCQB(R) Venture Market
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. ("CCMC" or the "Company") (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration company, is pleased to announce that its common shares have been approved for listing on the OTCQB Venture Market, operated by OTC Markets Group Inc. The Company's shares now trade on the OTCQB under the ticker symbol "CCMCF". In addition, the Company is pleased to confirm that its common shares have achieved Depository Trust Company ("DTC") eligibility, greatly facilitating the electronic clearing and settlement of its shares in the United States...
New Earth Resources Announces Private Placement
Vancouver, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- NEW EARTH RESOURCES CORP. (CSE: EATH) ("New Earth" or the "Company") is pleased to announce that it will be conducting a non-brokered private placement (the “Offering”) under which it will raise aggregate gross proceeds of up to $500,000 through the issuance of up to 4,166,667 units (each, a “Unit”) at a price of $0.12 per Unit. Each Unit will consist of one Class A common share (each, a “Share”) and one Share purchase warrant (each, a “Warrant”, entitling the holder to purchase one Share at a price of $0.18 for five years from the date of issuance)...
FCHL Receives Nasdaq Deficiency Notice on May 26, 2026
SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- On May 26, 2026, Fitness Champs Holdings Limited (“Fitness Champs Holdings”, “FCHL” or the “Company”) (NASDAQ: FCHL), a distinguished aquatic sports education provider in Singapore, received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), because (i) the stockholders' equity of the Company of $598,490 as of December 31, 2025, as reported in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, was below the minimum stockholders' equity requirement of $2,500,000 and (ii) the Company did not, as of May 26, 2026, meet the alternatives standards of market value of listed securities or net income from continuing operations for compliance with Nasdaq Listing Rule 5550(b)(1). Based on the proceeds of funds from a financing completed in May 2026, the Company believes it is now in compliance with the stockholders' equity requirements of Nasdaq Listing Rule 5550(b)(1); however the final determination of compliance is subject to review and approval by Nasdaq...
Ferrari Films Issues Formal Rebuttal to Forbes Article Mischaracterizing Section 168(k) as "Worthless" for Film Investors
LOS ANGELES--(BUSINESS WIRE)-- #168rules--Ferrari Films founder, attorney, and producer Stacy Kemp Ferrari today issued a point-by-point rebuttal to a Forbes article asserting that Section 168(k) of the Internal Revenue Code is "worthless as a tax shelter to raise financing for films." Ferrari contends the article contains critical legal oversights that, if left unchallenged, could mislead investors and producers who may have entirely lawful and well-structured grounds to benefit from the statute. "This ar...
AISIX Solutions Inc. Provides Status Report of Annual Financial Statements and MD&A
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - AISIX Solutions Inc. (TSXV: AISX) ("AISIX" or the "Company") provides this bi-weekly default status report in accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The Company previously announced on May 1, 2026 that the British Columbia Securities Commission had issued a management cease trade order ("MCTO") further to the Company's application to the applicable securities regulatory authorities in Canada on the basis that the Company's audited annual financial statements, management's discussion and analysis and the applicable CEO and CFO certificates for the financial year ended December 31, 2025 (collectively, the "Annual Filings") would not be filed by the applicable filing deadline of April 30, 2026 (the "Default Announcement")...
Gold Basin Resources Provides Updates on Arrangement with CANEX
VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Gold Basin Resources Corporation ("Gold Basin") (TSXV:GXX) announces updates with respect to the previously announced proposed arrangement (the "Arrangement") with CANEX Metals Inc. ("CANEX"). Reference is made to the arrangement agreement between Gold Basin and CANEX, dated May 11, 2026 (the "Arrangement Agreement"), and the management information circular dated May 14, 2026 in connection with Gold Basin's special meeting (the "Meeting") of shareholders ("Gold Basin Shareholders") to be held on June 4, 2026 with respect to the Arrangement (the "Arrangement Circular")...
Acceleware Ltd. Reports First Quarter 2026 Financial and Operating Results
Calgary, Alberta--(Newsfile Corp. - May 29, 2026) - Acceleware Ltd. (TSXV: AXE) ("Acceleware" or the "Company"), today announced its financial and operating results for the three months ended March 31, 2026 (all figures are in Canadian dollars unless otherwise noted).
Gap Inc. Investigation Initiated: SueWallSt Investigates the Officers and Directors of Gap Inc. (GAP)
Gap Inc. reported 1% Q1 revenue growth to $3.5 billion, missing Wall Street estimates, while Old Navy comparable sales came in at just 1% versus the 3% analysts expected -- shares fell over 15% in a single session. NEW YORK, May 29, 2026 /PRNewswire/ -- Investors who held Gap Inc. (NYSE: GAP) shares lost more than 15% of their investment on May 28-29, 2026, after the company reported Q1 FY2026 revenue of $3.5 billion -- up 1% year-over-year and below analyst expectations...
New Zealand Energy Corp. Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - New Zealand Energy Corp. (TSXV: NZ) ("NZEC" or the "Company") reports that further to the Company's news releases dated May 1 and 14, 2026 regarding the issuance of a management cease trade order by the British Columbia Securities Commission in connection with the delay in filing its annual disclosure documents (collectively, the "Annual Filings") for the year ended December 31, 2025 (the "MCTO News Release"), the Company confirms that work on the required documents is continuing and progressing. The Company continues to work closely with its independent reserves evaluator and external auditors to complete the reserves evaluation process and finalize the audited annual consolidated financial statements as expeditiously as possible...
Delivra Health and Its Brands Dream Water(R) and LivRelief(TM) Report Results for Third Quarter of Fiscal 2026
Third quarter sales reflect the impact of the continued changes in the global geopolitical landscape that has temporarily impacted outbound shipments from the USA to the Middle East distribution partners Third quarter sales and year-to-date sales growth of Dream Water Canada E-commerce of 16% and 13% respectively offset by a decline in Dream Water Canada Retail of 15% and 6% respectively compared to same periods last year Third quarter sales and year-to-date sales growth of LivRelief™ E-commerce of 60% and 32% respectively offset by a decline in LivRelief™ Retail of 30% and 27% respectively compared to same periods last year Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce its financial and operating results for the three and nine months ended March 31, 2026. The Delivra Health portfolio features innovative brands Dream Water and LivRelief™, which deliver relief from common health issues such as sleeplessness, chronic pain and anxiety...
Clean Energy Technologies Receives Notice of Deficiency from Nasdaq
IRVINE, CA, May 29, 2026 (GLOBE NEWSWIRE) -- Clean Energy Technologies, Inc. (Nasdaq: CETY) (“CETY” or the “Company”), a clean energy technology and solutions provider focused on converting waste and heat into power and fuels, announces that on May 26, 2026, it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”) because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the “Quarterly Report”)...
ThreeD Capital Inc. Releases Results For the Three and Nine Months Ended March 31, 2026
TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQB:IDKFF), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, is pleased to announce its unaudited results as at and for the three and nine months ended March 31, 2026...
K92 Mining Announces Voting Results of Annual General Meeting of Shareholders
VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce the voting results of its 2026 annual general meeting (“AGM”) of shareholders that was held today as a hybrid virtual and in-person event. All of the resolutions proposed at the AGM were duly passed...
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
Together the allowances deepen protection across two priority franchises and reinforce a patent estate of approximately 250 issued and pending patents and patent applications worldwide NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has issued Notices of Allowance for two patent applications spanning the Company's Actimab-A and Iomab-ACT programs. The allowances broaden Actinium's intellectual property protection across both hematologic malignancies and next-generation conditioning for gene-edited cell-based therapies in Canada, an important market within the Company's growing global patent estate...
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
NEW YORK, May 29, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class Actinium-225 (225Ac) antibody radioconjugate, ATNM-400, highlighting new data that will be showcased across three presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, taking place May 30-June 2, 2026, in Los Angeles, California. Two of the presentations showcase ATNM-400's differentiated profile across prostate cancer and non-small cell lung cancer (NSCLC), while a third demonstrates the importance of radioconjugate optimization for radiotherapies in the context of the Company's pipeline candidates...
Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $DOCKF #Blockchain--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (OTCQB: DOCKF) (“Republic” or the "Company") today provided an update with respect to its previously announced management cease trade order ("MCTO") in connection with the Company's filing of its audited annual financial statements (the " Financial Statements") and management discussion and analysis (the "MD&A") for the financial year ended December 31, 2025, and the applicable CEO and CFO certi...
Hydro One seeks approval from the Ontario Energy Board to build the Orléans Area Reinforcement Project
This investment will support economic growth in the Ottawa area TORONTO, May 29, 2026 /PRNewswire/ - Today, Hydro One Networks Inc. (Hydro One) announced it has filed a leave-to-construct application with the Ontario Energy Board (OEB) to seek approval to build the Orléans Area Reinforcement Project. The Orléans Area Reinforcement Project includes the construction of a new 11-kilometre 115-kilovolt (kV) transmission line within an existing transmission corridor between Hawthorne Transformer Station (TS) and Orléans TS, located in the Greater Ottawa Area...
$910 Million Student Housing Portfolio Sale Facilitated by Institutional Property Advisors
PHOENIX--(BUSINESS WIRE)---- $mmi #apartmentinvestments--$910 Million Student Housing Portfolio Sale Facilitated by Institutional Property Advisors.